JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us
このページは機械翻訳されています。他のページは英語で表示される場合があります。 View in English

手術後のクローン病の再発を防ぐための医療療法:体系的なレビューとネットワークメタ解析

  • 0Ellen Leifer Shulman and Steven Shulman Digestive Disease Center, Cleveland Clinic Florida, Weston, FL, United States; Department of General Surgery, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Israel.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract +

|

2025年8月21日

|

2025年8月21日

PubMedで要約を見る

まとめ

この要約は機械生成です。

アダリムマブは手術後のクローン病の再発を効果的に予防し,内視鏡検査および臨床再発率は他の治療法よりも低い. しかし,重度の有害事象のリスクが高くなります.

科学分野

  • 胃腸内科
  • 臨床薬理学
  • 手術 の 結果

背景

  • クローン病の術後の再発は重要な臨床的課題です.
  • CDの再発に対する現在の予防的な治療法は,最適な治療法の選択のための決定的な証拠がない.
  • この研究は,手術後のCD再発を防ぐための医療療法における比較効果の研究の必要性に対処しています.

研究 の 目的

  • 手術後のクローン病の再発を防ぐための様々な治療法を比較するネットワークメタ解析を行う.
  • 内視鏡検査と臨床再発率の減少における様々な治療戦略の有効性を評価する.
  • これらの治療に関連する重度の有害事象を含む安全性プロフィールを評価する.

主な方法

  • 過去20年間に発表されたランダム化対照試験 (RCT) の体系的レビューとPRISMA準拠のネットワークメタ解析.
  • クローン病の術後の再発に対する2つ以上の治療法を比較したRCTを主要なデータベース (PubMed,Scopus) で検索した.
  • バイアスのリスク 2 ツールを使用してバイアスのリスクを評価し,内視鏡再発,臨床再発,重度の有害事象に焦点を当てた.

主要な成果

  • アダリムマブは,アミノサリシル酸 (ASA),アザチオプリン,プロバイオティクス,プラセボと比較して,内視再発の確率が有意に低いことを示した.
  • アダリムマブはまた,ASA,アザチオプリン,プラセボと比較して,臨床再発の確率は有意に低下した.
  • アダリムマブは,重度の有害事象の増加と関連しているものの,内視鏡検査と臨床再発の両方を予防する点で最高にランク付けされました.

結論

  • アダリムマブとインフリキシマブだけが,プラセボと比較して臨床的および内視的再発を有意に減少させた.
  • アダリムマブは,手術後のクローン病の再発の予防薬として高い評価を得ています.
  • アダリムマブの利点と重度の有害事象のリスクの増大を考慮する必要があります.

キーワード:

関連する概念動画

Inflammatory Bowel Disease V: Surgical Management 01:21

212

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:

Strictureplasty
Proctocolectomy or total colectomy with ileostomy
Restorative proctocolectomy with Ileal pouch-anal anastomosis

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents 01:29

267

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Inflammatory Bowel Disease IV: Pharmacological Management 01:29

189

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids 01:21

202

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF 01:24

231

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy 01:30

419

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...